ライフサイエンスコーパス: prostaglandin F

1 ntation significantly reduced mucosal 6-keto-prostaglandin F(1 alpha) concentrations.

2 ly reduced the excretion of 2,3-dinor-6-keto prostaglandin F(1 alpha) in these animals.

3 -dinor thromboxane B(2) and 2,3-dinor-6-keto prostaglandin F(1 alpha), metabolites of thromboxane and

4 ary excretion of thromboxane B(2) and 6-keto-prostaglandin F(1)(alpha) and the ratio of the 2 compoun

5 te and nitrite (+36% versus +2%), and 6-keto-prostaglandin F(1alpha) (+71% versus +1%), whereas it de

6 ogen (BUN); thromboxane B2 (TXB2) and 6-keto prostaglandin F(1alpha) (6 kPGF(2alpha)) levels; creatin

7 ecrosis factor-alpha (TNF-alpha), and 6-keto prostaglandin F(1alpha) (6-kepto PGF(1alpha)).

8 elial cells synthesized twice as much 6-keto-prostaglandin F(1alpha) (P<0.01) and 16% less leukotrien

9 he prostacyclin metabolite 2, 3-dinor-6-keto-prostaglandin F(1alpha) (P:=0.04).

10 Immunoassays of VEGF-induced 6-keto prostaglandin F(1alpha) formation as an indicator of PGI

11 Plasma levels of nitrate and nitrite, 6-keto-prostaglandin F(1alpha), endothelin-1, asymmetrical dime

12 oxane B(2) (TXB(2)) and prostacyclin (6-keto prostaglandin F(1alpha); 6-keto PGF(1alpha)) metabolite

13 Prostaglandin F(2 alpha) (PGF(2 alpha)) receptors are G-

14 Despite structural similarity with prostaglandin F(2 alpha), the ocular hypotensive agent b

15 concentrations of an F(2)-isoprostane, 8-epi-prostaglandin F(2)(alpha) (8-epi-PGF(2)(alpha)), a bioma

16 Prostaglandin F(2)alpha (PGF(2)alpha) binding to its rec

17 Nasal prostaglandin F(2a), prostaglandin D(2) metabolites, leu

18 tent organic nitrate administration on 8-epi prostaglandin F(2alpha) (8-epi PGF(2alpha)) content and

19 Most research examined urinary 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)) as the oxida

20 ing kidneys showed >2-fold increase in 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)) levels compa

21 veloped for the measurement of urinary 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)), a biomarker

22 mean changes (and 95% CIs) in urinary 8-iso-prostaglandin F(2alpha) (pg/mg creatinine) were 9.0 (-12

23 shown that stimulation of both isoforms with prostaglandin F(2alpha) (PGF(2alpha)) activates the smal

24 Prostaglandin F(2alpha) (PGF(2alpha)) acts as a female r

25 erential effects of two hormonal pheromones, prostaglandin F(2alpha) (PGF(2alpha)) and 17alpha,20beta

26 isoprostanes are stereo- and regioisomers of prostaglandin F(2alpha) (PGF(2alpha)) and are used as bi

27 In fishes, prostaglandin F(2alpha) (PGF(2alpha)) drives mating and

28 Prostaglandin F(2alpha) (PGF(2alpha)) exerts its biologi

29 The mechanisms by which prostaglandin F(2alpha) (PGF(2alpha)) increases intracel

30 We have previously demonstrated that prostaglandin F(2alpha) (PGF(2alpha)) induces a rapid an

31 Prostaglandin F(2alpha) (PGF(2alpha)) is a potent antiad

32 As one of the major PGs, prostaglandin F(2alpha) (PGF(2alpha)) is present in huma

33 P) are G protein-coupled receptors that bind prostaglandin F(2alpha) (PGF(2alpha)), resulting in the

34 chidonic acid (AA) that are stereoisomers of prostaglandin F(2alpha) (PGF(2alpha)).

35 2)>6-keto prostaglandin F1alpha (PGF1alpha), prostaglandin F(2alpha) (PGF2alpha), and prostaglandin D

36 s G(q) in preference to G(13), whereas 8-iso-prostaglandin F(2alpha) activates G(13) in preference to

37 Prostaglandin F(2alpha) analogues are effective intraocu

38 ally, rings from remodeled LCs contracted to prostaglandin F(2alpha) and relaxed to acetylcholine in

39 actions of other neurohormones (endothelin, prostaglandin F(2alpha) angiotensin II) that also act on

40 onatal uterus was responsive to carbachol or prostaglandin F(2alpha) application; it showed a marked

41 Dietary fatty acids affect endogenous prostaglandin F(2alpha) concentrations and may thus infl

42 ntrations nor the percentage change in 8-iso-prostaglandin F(2alpha) differed significantly among tre

43 Prostaglandin F(2alpha) dose-dependently elevates blood

44 crog/mL of either latanoprost (free acid) or prostaglandin F(2alpha) ethanolamide and compared with c

45 Little is known about prostaglandin F(2alpha) in cardiovascular homeostasis.

46 To clarify this, the 8-iso-PGF(2alpha)/prostaglandin F(2alpha) ratio approach was used to quant

47 exes is identified here as FPRP, the 133-kDa prostaglandin F(2alpha) receptor regulatory protein.

48 Prostaglandin F(2alpha) receptors (FP) are G protein-cou

49 ither the FP(A) or the FP(B) receptor cDNAs, prostaglandin F(2alpha) stimulates inositol phosphate ac

50 effect of these 2 vitamins on urinary 8-iso-prostaglandin F(2alpha) was observed (P = 0.12).

51 xposed to Ad.CMVeNOS, maximum contraction to prostaglandin F(2alpha) was reduced compared with viral

52 1401 U/L), blood urea (53 mg/dl), and 8-iso-prostaglandin F(2alpha), a marker of oxidative stress (3

53 ng blood glucose, and the excretion of 8-iso-prostaglandin F(2alpha), a measure of oxidative stress,

54 LC-MS/MS) method to quantify 2,3-dinor-8-iso prostaglandin F(2alpha), a urinary metabolite of 8-iso-p

55 n and quantification of different isomers of prostaglandin F(2alpha), including 8-iso-PGF(2alpha), fo

56 alpha(1)-adrenergic agonists, endothelin-1, prostaglandin F(2alpha), interleukin 1beta, and phorbol

57 Isomers of prostaglandin F(2alpha), the F(2)-isoprostanes, have eme

58 were changes from baseline in urinary 8-iso-prostaglandin F(2alpha), urinary malondialdehyde + 4-hyd

59 d urinary excretion of the isoprostane 8-iso-prostaglandin F(2alpha), which is an indicator of oxidat

60 ssure and contractile force were measured in prostaglandin F(2alpha)-constricted hearts.

61 Quantification of a group of prostaglandin F(2alpha)-like compounds derived from the

62 ose, tocotrienols and tocopherols, and 8-iso-prostaglandin F(2alpha).

63 indicated by an increase in cytosolic 8-iso prostaglandin F(2alpha).

64 (iPs) are free radical-catalyzed isomers of prostaglandin F(2alpha).

65 din F(2alpha), a urinary metabolite of 8-iso-prostaglandin F(2alpha.) Urine was purified by solid-pha

66 d receptors whose physiological activator is prostaglandin-F(2alpha) (PGF(2alpha)).

67 (protein carbonyls, oxidized LDLs, and 8-iso-prostaglandin-F(2alpha)) were measured at baseline and 6

68 fect in reducing protein carbonyls and 8-iso-prostaglandin-F(2alpha); the reductions were 6-8% and 4-

69 ncentrations of tumor necrosis factor (TNF), prostaglandin F(6-keto-PGF1 alpha), and interleukin (IL)

70 alpha that no ligand tested, including 8-iso-prostaglandin F (8-iso-PGF2alpha and a purported antagon

71 ly in the potential of the isoprostane 8-iso-prostaglandin F (8-iso-PGF2alpha), among other ligands e

72 l C(1) alkylphosphinic acid analogues of the prostaglandin-F family have been evaluated at the eight

73 Omidenpag isopropyl (OMDI) in comparison to prostaglandin F(FP) agonists used in glaucoma management

74 P (1.55-fold), Isoprostane-8 (1.34-fold) and prostaglandin F metabolites (1.97-fold) were lower in CO

75 e potent and selective ligands for the human prostaglandin F receptor (hFP receptor).

76 The human prostaglandin F receptor (hFP-R) is widely expressed in

77 ivity was not limited to TP receptor because prostaglandin F receptor activated with U46619 and prost

78 type-4 chemokine receptors, but not for the prostaglandin F receptor that cannot interact with beta-

79 le 2, potassium inwardly-rectifying channel, prostaglandin F receptor, and RXR-beta cis-11-retinoic a

80 rm of which is a dual agonist targeting both prostaglandin F receptors and prostaglandin E receptor 3

81 We found that agonist-mediated activation of prostaglandin F receptors and prostaglandin E(2) recepto

82 Prostaglandin F synthase (PGFS) has dual catalytic activ

83 Prostaglandin F synthase (PGFS) was first purified from

84 We infer from the phylogenetic analysis that prostaglandin F synthase may represent a recent recruit

85 ebrate hydroxysteroid dehydrogenase enzymes, prostaglandin F synthase, and rho-crystallin of Xenopus

86 rostaglandin F synthases, such as prostamide/prostaglandin F synthase, to prostaglandin F2alpha ethan

87 ndamide may be converted by PTGS2 (COX2) and prostaglandin F synthases, such as prostamide/prostaglan